Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M
Published in Leukemia (01.05.2016)
Published in Leukemia (01.05.2016)
Get full text
Journal Article
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
Stone, R M, Fischer, T, Paquette, R, Schiller, G, Schiffer, C A, Ehninger, G, Cortes, J, Kantarjian, H M, DeAngelo, D J, Huntsman-Labed, A, Dutreix, C, del Corral, A, Giles, F
Published in Leukemia (01.09.2012)
Published in Leukemia (01.09.2012)
Get full text
Journal Article
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
DiNardo, C.D., Tiong, I.S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F.C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J.M., Glytsou, C., Fleming, S.A., Zhang, Q., Ma, H., Patel, K.P., Kornblau, S.M., Xu, Z., Chua, C.C., Chen, Xufeng, Blombery, P., Flensburg, C., Cummings, N., Aifantis, I., Kantarjian, H., Huang, D.C.S, Roberts, A.W., Majewski, I.J., Konopleva, M., Wei, A.H.
Published in Blood (12.03.2020)
Published in Blood (12.03.2020)
Get full text
Journal Article
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Larson, R A, Hochhaus, A, Hughes, T P, Clark, R E, Etienne, G, Kim, D-W, Flinn, I W, Kurokawa, M, Moiraghi, B, Yu, R, Blakesley, R E, Gallagher, N J, Saglio, G, Kantarjian, H M
Published in Leukemia (01.10.2012)
Published in Leukemia (01.10.2012)
Get full text
Journal Article
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
Walter, R B, Othus, M, Burnett, A K, Löwenberg, B, Kantarjian, H M, Ossenkoppele, G J, Hills, R K, Ravandi, F, Pabst, T, Evans, A, Pierce, S R, Vekemans, M-C, Appelbaum, F R, Estey, E H
Published in Leukemia (01.02.2015)
Published in Leukemia (01.02.2015)
Get full text
Journal Article
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Yang, H, Bueso-Ramos, C, DiNardo, C, Estecio, M R, Davanlou, M, Geng, Q-R, Fang, Z, Nguyen, M, Pierce, S, Wei, Y, Parmar, S, Cortes, J, Kantarjian, H, Garcia-Manero, G
Published in Leukemia (01.06.2014)
Published in Leukemia (01.06.2014)
Get full text
Journal Article
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
Hochhaus, A, Baccarani, M, Deininger, M, Apperley, J F, Lipton, J H, Goldberg, S L, Corm, S, Shah, N P, Cervantes, F, Silver, R T, Niederwieser, D, Stone, R M, Dombret, H, Larson, R A, Roy, L, Hughes, T, Müller, M C, Ezzeddine, R, Countouriotis, A M, Kantarjian, H M
Published in Leukemia (01.06.2008)
Published in Leukemia (01.06.2008)
Get full text
Journal Article
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications
Fabbri, M, Garzon, R, Andreeff, M, Kantarjian, H M, Garcia-Manero, G, Calin, G A
Published in Leukemia (01.06.2008)
Published in Leukemia (01.06.2008)
Get full text
Journal Article
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
DiNardo, C D, Jabbour, E, Ravandi, F, Takahashi, K, Daver, N, Routbort, M, Patel, K P, Brandt, M, Pierce, S, Kantarjian, H, Garcia-Manero, G
Published in Leukemia (01.04.2016)
Published in Leukemia (01.04.2016)
Get full text
Journal Article
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy
DiNardo, C D, Daver, N, Jain, N, Pemmaraju, N, Bueso-Ramos, C, Yin, C C, Pierce, S, Jabbour, E, Cortes, J E, Kantarjian, H M, Garcia-Manero, G, Verstovsek, S
Published in Leukemia (01.04.2014)
Published in Leukemia (01.04.2014)
Get full text
Journal Article
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
le Coutre, P D, Giles, F J, Hochhaus, A, Apperley, J F, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N J, Baccarani, M, Cortes, J, Kantarjian, H M
Published in Leukemia (01.06.2012)
Published in Leukemia (01.06.2012)
Get full text
Journal Article
Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
Othus, M, Kantarjian, H, Petersdorf, S, Ravandi, F, Godwin, J, Cortes, J, Pierce, S, Erba, H, Faderl, S, Appelbaum, F R, Estey, E
Published in Leukemia (01.02.2014)
Published in Leukemia (01.02.2014)
Get full text
Journal Article
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G
Published in Leukemia (01.05.2012)
Published in Leukemia (01.05.2012)
Get full text
Journal Article
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
Giles, F J, le Coutre, P D, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Radich, J P, Saglio, G, Hughes, T P, Martinelli, G, Kim, D-W, Novick, S, Gillis, K, Fan, X, Cortes, J, Baccarani, M, Kantarjian, H M
Published in Leukemia (01.01.2013)
Published in Leukemia (01.01.2013)
Get full text
Journal Article
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Gökbuget, N, Kelsh, M, Chia, V, Advani, A, Bassan, R, Dombret, H, Doubek, M, Fielding, A K, Giebel, S, Haddad, V, Hoelzer, D, Holland, C, Ifrah, N, Katz, A, Maniar, T, Martinelli, G, Morgades, M, O'Brien, S, Ribera, J-M, Rowe, J M, Stein, A, Topp, M, Wadleigh, M, Kantarjian, H
Published in Blood cancer journal (New York) (23.09.2016)
Published in Blood cancer journal (New York) (23.09.2016)
Get full text
Journal Article
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
SINGER, J. B, SHOU, Y, OTTMANN, O. G, GILES, F, KANTARJIAN, H. M, HSU, Y, ROBEVA, A. S, RAE, P, WEITZMAN, A, MEYER, J. M, DUGAN, M
Published in Leukemia (01.11.2007)
Published in Leukemia (01.11.2007)
Get full text
Journal Article
A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome
Kelly, A D, Kroeger, H, Yamazaki, J, Taby, R, Neumann, F, Yu, S, Lee, J T, Patel, B, Li, Y, He, R, Liang, S, Lu, Y, Cesaroni, M, Pierce, S A, Kornblau, S M, Bueso-Ramos, C E, Ravandi, F, Kantarjian, H M, Jelinek, J, Issa, J-PJ
Published in Leukemia (01.10.2017)
Published in Leukemia (01.10.2017)
Get full text
Journal Article